GSK is investing $800 million to expand its manufacturing site in Marietta, Pennsylvania, focusing on sterile liquid vaccines and drug substances, with operations expected by 2027 and 2028. Amgen has set a list price of $1,665 for its Eylea biosimilar, Pavblu, launching without a legal settlement, which may lead to penalties if future rulings favor Regeneron. Meanwhile, Roche has partnered with Dyno Therapeutics for gene therapy advancements, and AbbVie is collaborating with Gideon Richter on neuropsychiatric treatments. Marinus Pharmaceuticals is laying off staff after its seizure drug ganaxolone failed to meet Phase 3 study goals.
Pfizer has invested $49 million in Triana Biomedicines to develop molecular glue degraders for oncology, while Tim Buckley joins Pfizer's board amid pressure from activist investors. Jazz Pharmaceuticals reported positive Phase 3 results for Zepzelca in small cell lung cancer, prompting plans for expanded FDA approval. MeiraGTx's gene therapy for Parkinson's disease showed safety and encouraging efficacy in a small trial, and Akeso raised $250 million for international trials of its antibody drugs. Inventiva appointed Mark Pruzanski as chairman, securing $100 million for a Phase 3 trial of lanifibranor.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
